Targeting tumor immune microenvironment enhances anti-tumor activity of KRAS G12D Inhibitor RNK08954
The effect of RNK08954 on modulating the tumor immune microenvironment (TIME) was studied in immune-competent mouse syngeneic model. RNK08954 administration at a dose of 100 mg/kg exhibited best response in subcutaneous CT-26-derived mouse syngeneic model. Immune phenotyping of tumor samples 24 hours post-dose using a single cell RNA-sequence (scRNA-seq).